Header Logo

Connection

Shan Lu to Animals

This is a "connection" page, showing publications Shan Lu has written about Animals.
Connection Strength

1.043
  1. Li H, Wang S, Hu G, Zhang L, Liu S, Lu S. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. Emerg Microbes Infect. 2021 Dec; 10(1):833-841.
    View in: PubMed
    Score: 0.053
  2. Wang S, Voronin Y, Zhao P, Ishihara M, Mehta N, Porterfield M, Chen Y, Bartley C, Hu G, Han D, Wells L, Tiemeyer M, Lu S. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions. J Virol. 2020 03 17; 94(7).
    View in: PubMed
    Score: 0.047
  3. Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020; 9(1):542-544.
    View in: PubMed
    Score: 0.047
  4. Farf?n-Arribas DJ, Liu S, Wang S, Lu S. The dynamics of immunoglobulin V-gene usage and clonotype expansion in mice after prime and boost immunizations as analyzed by NGS. Hum Vaccin Immunother. 2017 12 02; 13(12):2987-2995.
    View in: PubMed
    Score: 0.040
  5. Wang S, Chou TH, Hackett A, Efros V, Wang Y, Han D, Wallace A, Chen Y, Hu G, Liu S, Clapham P, Arthos J, Montefiori D, Lu S. Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. Hum Vaccin Immunother. 2017 12 02; 13(12):2996-3009.
    View in: PubMed
    Score: 0.039
  6. Suschak JJ, Wang S, Fitzgerald KA, Lu S. A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol. 2016 Jan 01; 196(1):310-6.
    View in: PubMed
    Score: 0.035
  7. Suschak JJ, Wang S, Fitzgerald KA, Lu S. Identification of Aim2 as a sensor for DNA vaccines. J Immunol. 2015 Jan 15; 194(2):630-6.
    View in: PubMed
    Score: 0.032
  8. Lu S. Editorial overview: vaccines against challenging viral pathogens and new vaccine technology. Curr Opin Virol. 2014 Jun; 6:viii-ix.
    View in: PubMed
    Score: 0.031
  9. Buglione-Corbett R, Pouliot K, Marty-Roix R, Li W, West K, Wang S, Morelli AB, Lien E, Lu S. Reduced MyD88 dependency of ISCOMATRIX? adjuvant in a DNA prime-protein boost HIV vaccine. Hum Vaccin Immunother. 2014; 10(4):1078-90.
    View in: PubMed
    Score: 0.031
  10. Lu S. Novel vaccine technology and the future of vaccine science. Hum Vaccin Immunother. 2014; 10(5):1143-6.
    View in: PubMed
    Score: 0.030
  11. Wang S, Lu S. DNA immunization. Curr Protoc Microbiol. 2013 Nov 05; 31:18.3.1-18.3.24.
    View in: PubMed
    Score: 0.030
  12. Buglione-Corbett R, Pouliot K, Marty-Roix R, West K, Wang S, Lien E, Lu S. Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One. 2013; 8(9):e74820.
    View in: PubMed
    Score: 0.030
  13. Gil A, Shen S, Coley S, Gibson L, Diamond DJ, Wang S, Lu S. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. Hum Vaccin Immunother. 2013 Oct; 9(10):2120-32.
    View in: PubMed
    Score: 0.029
  14. Almansour I, Chen H, Wang S, Lu S. Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother. 2013 Oct; 9(10):2049-59.
    View in: PubMed
    Score: 0.029
  15. Chen Y, Vaine M, Wallace A, Han D, Wan S, Seaman MS, Montefiori D, Wang S, Lu S. A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol. 2013 Sep; 87(18):10232-43.
    View in: PubMed
    Score: 0.029
  16. Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol. 2011 May; 85(10):4927-36.
    View in: PubMed
    Score: 0.025
  17. Wang S, Goguen JD, Li F, Lu S. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine. 2011 Sep 09; 29(39):6802-9.
    View in: PubMed
    Score: 0.025
  18. Wang S, Mboudjeka I, Goguen JD, Lu S. Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines. Vaccine. 2010 Feb 23; 28(8):2011-9.
    View in: PubMed
    Score: 0.023
  19. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010 Apr 09; 28(17):2999-3007.
    View in: PubMed
    Score: 0.023
  20. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009 Jun; 21(3):346-51.
    View in: PubMed
    Score: 0.022
  21. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol. 2008 Aug; 82(15):7369-78.
    View in: PubMed
    Score: 0.021
  22. Wang S, Parker C, Taaffe J, Sol?rzano A, Garc?a-Sastre A, Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008 Jul 04; 26(29-30):3626-33.
    View in: PubMed
    Score: 0.021
  23. Wang S, Joshi S, Mboudjeka I, Liu F, Ling T, Goguen JD, Lu S. Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine. 2008 Mar 20; 26(13):1664-74.
    View in: PubMed
    Score: 0.020
  24. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology. 2008 Feb 05; 371(1):98-107.
    View in: PubMed
    Score: 0.020
  25. Shen S, Wang S, Britt WJ, Lu S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine. 2007 Apr 30; 25(17):3319-27.
    View in: PubMed
    Score: 0.019
  26. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol. 2006 Nov; 28(3):255-65.
    View in: PubMed
    Score: 0.018
  27. Wang S, Taaffe J, Parker C, Sol?rzano A, Cao H, Garc?a-Sastre A, Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol. 2006 Dec; 80(23):11628-37.
    View in: PubMed
    Score: 0.018
  28. Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology. 2006 Nov 25; 355(2):164-74.
    View in: PubMed
    Score: 0.018
  29. Biswas S, Langeveld JP, Tipper D, Lu S. Intracellular accumulation of a 46 kDa species of mouse prion protein as a result of loss of glycosylation in cultured mammalian cells. Biochem Biophys Res Commun. 2006 Oct 13; 349(1):153-61.
    View in: PubMed
    Score: 0.018
  30. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology. 2006 Jun 20; 350(1):34-47.
    View in: PubMed
    Score: 0.018
  31. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006 May 22; 24(21):4531-40.
    View in: PubMed
    Score: 0.017
  32. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005 Jun; 79(12):7933-7.
    View in: PubMed
    Score: 0.017
  33. Wang S, Sakhatskyy P, Chou TH, Lu S. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). J Immunol Methods. 2005 Jun; 301(1-2):21-30.
    View in: PubMed
    Score: 0.017
  34. Chou TH, Wang S, Sakhatskyy PV, Mboudjeka I, Mboudoudjeck I, Lawrence JM, Huang S, Coley S, Yang B, Li J, Zhu Q, Lu S. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2005 Mar 30; 334(1):134-43.
    View in: PubMed
    Score: 0.017
  35. Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005 Feb; 79(3):1906-10.
    View in: PubMed
    Score: 0.016
  36. Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, Chou TH, Goguen J, Lu S. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine. 2004 Sep 03; 22(25-26):3348-57.
    View in: PubMed
    Score: 0.016
  37. Liu F, Mboudjeka I, Shen S, Chou TH, Wang S, Ross TM, Lu S. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine. 2004 Apr 16; 22(13-14):1764-72.
    View in: PubMed
    Score: 0.016
  38. Chou TH, Biswas S, Lu S. Gene delivery using physical methods: an overview. Methods Mol Biol. 2004; 245:147-66.
    View in: PubMed
    Score: 0.015
  39. Wang S, Joshi S, Lu S. Delivery of DNA to skin by particle bombardment. Methods Mol Biol. 2004; 245:185-96.
    View in: PubMed
    Score: 0.015
  40. Kim H, Ding YH, Lu S, Zuo MQ, Tan W, Conte D, Dong MQ, Mello CC. PIE-1 SUMOylation promotes germline fates and piRNA-dependent silencing in C. elegans. Elife. 2021 05 18; 10.
    View in: PubMed
    Score: 0.013
  41. Palace SG, Proulx MK, Lu S, Baker RE, Goguen JD. Genome-wide mutant fitness profiling identifies nutritional requirements for optimal growth of Yersinia pestis in deep tissue. mBio. 2014 Aug 19; 5(4).
    View in: PubMed
    Score: 0.008
  42. Pouliot K, Buglione-Corbett R, Marty-Roix R, Montminy-Paquette S, West K, Wang S, Lu S, Lien E. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine. 2014 Sep 03; 32(39):5049-56.
    View in: PubMed
    Score: 0.008
  43. Wallace A, West K, Rothman AL, Ennis FA, Lu S, Wang S. Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). Hum Vaccin Immunother. 2013 Oct; 9(10):2095-102.
    View in: PubMed
    Score: 0.007
  44. Abdel-Motal UM, Wang S, Awad A, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. Vaccine. 2010 Feb 17; 28(7):1758-65.
    View in: PubMed
    Score: 0.006
  45. Vaine M, Lu S, Wang S. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs. 2009; 23(3):137-53.
    View in: PubMed
    Score: 0.005
  46. Pouliot K, Pan N, Wang S, Lu S, Lien E, Goguen JD. Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis. Infect Immun. 2007 Jul; 75(7):3571-80.
    View in: PubMed
    Score: 0.005
  47. Abdel-Motal U, Wang S, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol. 2006 Jul; 80(14):6943-51.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.